OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial
March 21, 2024 07:00 ET
|
OKYO Pharma LTD
-Phase 2 OK-101 efficacy data to be released March 22nd, 2024- -KOL Event to be held on April 9th, 2024 at 12 PM ET- LONDON and NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited...
OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event
March 20, 2024 07:00 ET
|
OKYO Pharma LTD
LONDON and NEW YORK, March 20, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions
December 18, 2023 09:00 ET
|
Cyclacel
- Patient Pharmacodynamic Data Show Decrease in CDKN2A, CDKN2B, and PRMT5 Protein Levels - - A Squamous Non-Small Cell Lung Cancer Patient with CDKN2B Deletion Achieved Marked Tumor Shrinkage...
Clinical Biomarkers Market Size to Reach USD 63.04 Billion in 2032 | Emergen Research
December 12, 2023 07:31 ET
|
Emergen Research
Vancouver, Dec. 12, 2023 (GLOBE NEWSWIRE) -- The global clinical biomarkers market is expected to reach a market size of USD 63.04 billion at a steady CAGR of 10.2% in 2032, according to latest...
GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Kenvue Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action Filed by the Firm – KVUE
October 15, 2023 22:13 ET
|
The Rosen Law Firm PA
NEW YORK, Oct. 15, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of...
Interim review of proprietary PsiGAD clinical trial data indicates no safety concerns and projects a statistically significant benefit for the psilocybin arm versus the placebo arm in those participants who have completed the treatment
March 15, 2023 07:30 ET
|
Incannex Healthcare
Highlights: Interim analysis of study data to date indicates that there is a greater than 85% chance (>85%, alpha error probability 0.05) of the study showing a statistically significant benefit...
Provectus Biopharmaceuticals Receives Notice of Allowance for Refractory Pediatric Solid Tumor Cancer Monotherapy and Combination Therapy Patent for PV-10® Immunotherapy from United States Patent and Trademark Office
March 23, 2021 07:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, March 23, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (USPTO) has allowed US patent application 16/412,872,...
Novavax to Present COVID-19 Vaccine Candidate Data at New York Academy of Science
February 01, 2021 19:32 ET
|
Novavax, Inc.
GAITHERSBURG, Md., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that...
Arch Biopartners Announces Dosing of First Patient in Turkey in Phase II Trial of LSALT peptide to Treat Complications from Covid-19
November 05, 2020 08:04 ET
|
Arch Biopartners
TORONTO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient dosing in Turkey has begun in the Phase...
Grapefruit/IGNG Announces Successful Results in Initial Tests for Efficacy of its Patented Time-Release THC Cannabinoid “Patchless Patch™”
January 08, 2020 06:00 ET
|
Imaging3, Inc.
Los Angeles/Desert Hot Springs, CA, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Grapefruit Boulevard Investments, Inc., (“GBI”) a California based cannabis company and a wholly owned subsidiary of Imaging3,...